Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant
CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with …

Background Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF
V600E kinase–activating mutation plays a pathogenetic role. In clinical trials involving …

Abstract BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We
report the efficacy and safety of dabrafenib plus trametinib in patients with …

Background Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here,
we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial …

Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has
been developed by MedImmune and its parent company AstraZeneca for the treatment of …

Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel
treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent …

Disease overview Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant
(HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group …

PURPOSE Single-agent purine analog, usually cladribine, has been the standard first-line
therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often …